Stamford Pharmaceuticals

TX - AustinPharmaceutical2 H-1B visas (FY2023)

Focus: Stamford Pharmaceuticals is an immunotherapy-focused pharmaceutical company headquartered in Austin, TX, specializing in neurology and oncology programs. Scale and financial details remain undisclosed.

Neurology

Profile data last refreshed 20h ago · AI intelligence enriched 2w ago

Open Jobs

About Stamford Pharmaceuticals

AI assessmentNot Hiring

No open roles listed right now. Follow Stamford Pharmaceuticals to get notified when they start hiring — the background below is worth knowing for when they do.

Why Work Here

Data completeness

1/9 — Limited

Company HealthStrong

Pipeline

Late-stage

3 Phase 3+

LOE Risk

Protected

No near-term cliffs

Hiring

0 open

Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.

Pipeline & Clinical Trials

targon pft nail

Hip Fracture

N/A

Clinical Trials (1)

NCT02680028Short Versus Standard Intramedullary Nail for Trochanteric Hip Fractures

N/A

Help build intelligence for Stamford Pharmaceuticals

No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.

Share Interview Share Compensation

Data Sources

Drug label: DailyMed / FDA
Clinical trials: ClinicalTrials.gov
Patent data: FDA Orange Book
Spending data: CMS Medicare

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.

Portfolio spans 18 active programs across oncology (basal cell carcinoma, pancreatic cancer, lung cancer), neurology, and supportive care with programs in Phase 1–4 development
Immunotherapy specialization positions the company in a high-growth therapeutic area with significant unmet medical need
100% H1B approval rate (2/2 in 2023) signals openness to international talent recruitment

Watch Out For

Extremely limited hiring footprint (2 active roles across Clinical Operations and R&D) suggests minimal growth or very early-stage operations
Unfocused pipeline with diverse indications (hip fractures, IBS, urinary incontinence, cancer) mixed with non-drug interventions (stretching, devices, surgical techniques) raises questions about strategic clarity and development rigor

Generated by Claude from Stamford Pharmaceuticals's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.

ReCIVA breath sampler

Lung Cancer

N/A

Clinical Trials (1)

NCT02612532Lung Cancer Indicator Detection

N/A

Hemiarthroplasty

Hip Fractures

N/A

Clinical Trials (1)

NCT02998359Hemiarthroplasty Versus Total Hip Replacement for Intracapsular Hip Fractures

N/A

Uncemented Furlong Hemiarthroplasty

Hip Fractures

N/A

Clinical Trials (1)

NCT02998034Cemented Hemiarthroplasty Versus Uncemented Furlong Hemiarthroplasty

N/A

TAP block

Abdominal Muscles/Ultrasonography

N/A

Clinical Trials (1)

NCT01589796Medial Versus Traditional Approach to US-guided TAP Blocks for Open Inguinal Hernia Repair

N/A

sliding hip screw

Hip Injuries

N/A

Clinical Trials (1)

NCT03172923Nail Versus Sliding Hip Screw for Trochanteric Hip Fractures

N/A

Internal fixation

Hip Fractures

N/A

Clinical Trials (1)

NCT02996383Fixation Versus Arthroplasty for Undisplaced Intracapsular Fractures

N/A

Diabetes Diagnosis

Diabetes Mellitus

N/A

Clinical Trials (1)

NCT05256043Investigation of Critically Ill Patients With Newly Diagnosed Diabetes

N/A

TAP catheter

Abdominal Muscles/Ultrasonography

N/A

Clinical Trials (1)

NCT01593280TAP Catheters Versus Intrathecal Morphine for Cesarean Section

N/A

GAX - Gemcitabine, Abraxane and Xeloda

Pancreatic Cancer

Phase 1

Clinical Trials (1)

NCT02581501Prospective Phase I Study of GAX for Metastatic Pancreatic Cancer

Phase 1

SP-002

Basal Cell Carcinoma

Phase 2

Clinical Trials (1)

NCT06344052To Assess the Safety and Efficacy of SP-002 with Vismodegib for the Treatment of Locally Advanced Basal Cell Carcinoma

Phase 2

Capsaicin

Myofascial Pain Syndrome

Phase 2

Clinical Trials (1)

NCT00795106Trial to Evaluate the Efficacy of Topical Capsaicin to Reduce Pain and Improve Health-related Quality of Life in Adults With Chronic Myofascial Neck Pain

Phase 2

Botanical Tincture

Irritable Bowel Syndrome Characterized by Constipation

Phase 2

Clinical Trials (1)

NCT03923322Botanical Tincture for Symptoms of Irritable Bowel Syndrome

Phase 2

lenalidomide

Multiple Myeloma

Phase 2

Clinical Trials (1)

NCT01463670Lenalidomide Intensification in Patients With Serologic/Asymptomatic Progression of Multiple Myeloma While on Lenalidomide Maintenance